Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most commonly mutated oncogenes in NSCLC, with a mutation incidence of approximately 25% in Western populations [2]; however, the incidence of KRAS mutation in adenocarcinoma in the Asian population is 5–15% [3]. This evidence concerns the gene KRAS and adenocarcinoma.